IDEA EV06
Status:Completed
Phase:I
Principal Investigator(s):Pontiano Kaleebu
Objective:To evaluate the safety and immunogenicity of the combination of DNA-HIV-PT123 and AIDSVAX B/E in HIV-1 uninfected adult participants with or without undelrying Schistosoma mansoni infection.
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Placebo
Arms and Assigned Interventions
DescriptionDNA-HIV-PT123 and AIDSVAX ® B/E
Mode of Delivery
ARMs
Official Code:
NCT02376582
Trial Sponsors:
EuroVacc Foundation, IAVI
Start Date
End Date
September 3, 2014
January 6, 2016
Enrollment:72
Age range:
18 Years ↔
45 Years
Population:Cisgender Men, Cisgender Women